PHARMACEUTICAL FORMULATIONS FOR TREATING DISEASES MEDIATED BY KDM1A

Provided is a pharmaceutical composition comprising: N-((S)-5-((1R,2S)-2-(4-fluorophenyl)cyclopropylamino)-1-(4-methylpiperazin-1-yl)-1-oxopentan-2-yl)-4-(1H-1,2,3-triazol-1-yl)benzamide (Compound A), or a pharmaceutically acceptable salt thereof, and at least one stabilizer, pharmaceutical preparat...

Full description

Saved in:
Bibliographic Details
Main Authors VED, Parag, CELATKA, Cassandra, VORA, Namrata, TAPPER, Amy, SOULLIAC, Patricia
Format Patent
LanguageEnglish
French
German
Published 09.08.2023
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Provided is a pharmaceutical composition comprising: N-((S)-5-((1R,2S)-2-(4-fluorophenyl)cyclopropylamino)-1-(4-methylpiperazin-1-yl)-1-oxopentan-2-yl)-4-(1H-1,2,3-triazol-1-yl)benzamide (Compound A), or a pharmaceutically acceptable salt thereof, and at least one stabilizer, pharmaceutical preparations thereof, and methods for the treatment a disease or disorder associated with KDM1A activity.
Bibliography:Application Number: EP20210876583